These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 30200528

  • 1. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
    Brooks N, Hsu J, Esparon S, Pouniotis D, Pietersz GA.
    Molecules; 2018 Sep 02; 23(9):. PubMed ID: 30200528
    [Abstract] [Full Text] [Related]

  • 2. Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides.
    Brooks N, Esparon S, Pouniotis D, Pietersz GA.
    Molecules; 2015 Aug 03; 20(8):14033-50. PubMed ID: 26247926
    [Abstract] [Full Text] [Related]

  • 3. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM, Kinarsky L, Caffrey T, Hanisch FG, Sanderson S, Hollingsworth MA, Sherman S.
    Int Immunopharmacol; 2005 Feb 03; 5(2):315-30. PubMed ID: 15652762
    [Abstract] [Full Text] [Related]

  • 4. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
    Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF.
    Vaccine; 2000 Apr 03; 18(19):2059-71. PubMed ID: 10706970
    [Abstract] [Full Text] [Related]

  • 5. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM, Vlad A, Finn OJ.
    Clin Cancer Res; 1999 Jul 03; 5(7):1918-24. PubMed ID: 10430099
    [Abstract] [Full Text] [Related]

  • 6. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI, Huang MH, Chang YW, Chen IH, Roffler S, Chen BM, Sher YP, Liu SJ.
    Cancer Lett; 2016 Jul 28; 377(2):126-33. PubMed ID: 27130449
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo.
    Tang XD, Wang GZ, Guo J, Lü MH, Li C, Li N, Chao YL, Li CZ, Wu YY, Hu CJ, Fang DC, Yang SM.
    Mol Cancer Ther; 2012 May 28; 11(5):1183-92. PubMed ID: 22442309
    [Abstract] [Full Text] [Related]

  • 12. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T, Uehara S, Ariga H, Tokunaga T, Kariyone A, Tamura T, Takatsu K.
    Immunology; 2006 Jan 28; 117(1):47-58. PubMed ID: 16423040
    [Abstract] [Full Text] [Related]

  • 13. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
    Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W.
    Blood; 1999 Jun 15; 93(12):4309-17. PubMed ID: 10361129
    [Abstract] [Full Text] [Related]

  • 14. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
    Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R.
    Int J Cancer; 2001 Feb 01; 91(3):385-92. PubMed ID: 11169964
    [Abstract] [Full Text] [Related]

  • 15. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Irie A, Kawahara K, Yatsuda J, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y.
    Clin Cancer Res; 2013 Aug 15; 19(16):4508-20. PubMed ID: 23714729
    [Abstract] [Full Text] [Related]

  • 16. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
    Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA.
    Immunol Cell Biol; 2011 Nov 15; 89(8):904-13. PubMed ID: 21383765
    [Abstract] [Full Text] [Related]

  • 17. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 18. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.
    Clin Cancer Res; 2002 Jan 15; 8(1):41-53. PubMed ID: 11801539
    [Abstract] [Full Text] [Related]

  • 19. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses.
    Newman KD, Sosnowski DL, Kwon GS, Samuel J.
    J Pharm Sci; 1998 Nov 15; 87(11):1421-7. PubMed ID: 9811500
    [Abstract] [Full Text] [Related]

  • 20. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
    Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY.
    Cancer Immunol Immunother; 2014 Feb 15; 63(2):161-74. PubMed ID: 24233342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.